Skip to content

IKTINHIBIKASE THERAPEUTICS INC

CUSIP 45719W205 · common stock

2 tracked investors held INHIBIKASE THERAPEUTICS INC (IKT) at the end of Q3 2026, worth $26.1M in total. The largest holder was RA Capital Management, with 0.1% of its portfolio. RA Capital Management opened a new position this quarter.

Holders · Q3 2026
2
New holders
1
Value held
$26.1M
Quarter-end price (est.)
$2.06

Investors holding IKT · Q3 2026

InvestorWeightSharesValueChange
RA Capital Management
RA Capital Management, L.P.
0.14%6,970,000$14.3MNEW
Adar1 Capital Management
ADAR1 Capital Management, LLC
0.50%5,708,755$11.7MREDUCE-22.7%

History

QuarterHoldersNewSold outValue heldQuarter-end price (est.)
Q3 2026210$26.1M$2.06
Q2 2026101$15M$2.03
Q1 2026200$15M$1.68
Q4 2025200$27.6M$2.05